ArticleCardiovascular drugs and therapy2026
Protease-activated Receptor 1 Targeted Screening of Potential Antithrombotic Compounds with Hemostatic Activity from Polygonum Amplexicaule D. Don var. Sinense Forb.
Article in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Response to: Refining Antithrombotic Therapy in Coronary Artery Ectasia.Cardiovascular drugs and therapy · 2026Article
- Hexosamine Biosynthetic Pathway and Fatty Acid β-Oxidative Imbalance: A Key Mechanism by Which Abnormal Macrophage Lipophagy Promotes Atherosclerosis in Diabetes.Cardiovascular drugs and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposethis study aims to screen Protease-activated receptor 1 (PAR1) inhibitory active components with low bleeding side effects from anti-thrombin phytochemicals in Polygonum amplexicaule D. Don var. sinense Forb (PAF) to achieve multi-pathway antithrombosis without disrupting platelet hemostasis.
methodsDocking simulation and platelet aggregation test were used to investigate interaction of PAR1-ligands to screen out anti-PAR1 active ingredients. FeCl
resultsThree promising ligands (epigallocatechin gallate, homoorientin, and myricetin) with strong affinity of PAR1 were selected from PAF. Epigallocatechin gallate and homoorientin showed antithrombotic effects with decreased bleeding tendency based on activity validation, suggesting that they may be prospective and effective candidate compounds of PAR1 antagonists.
conclusionthe integrative strategy applied to these active components allowed to rapidly discover compounds with reducing bleeding side effects during thrombus treatment, providing valuable references for precisely targeted therapy and mechanism exploration of medicinal plants.
Indexed as
Identifiers
41288862What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.